Total medical devices industry venture financing deals in Q3 2019 worth $1.33bn were announced in the US, according to GlobalData’s deals database.
Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 37.2% over the previous quarter and a drop of 23.5% when compared with the last four-quarter average of $1.74bn.
The US held a 58.9% share of the global medical devices industry venture financing deal value that totalled $2.26bn in Q3 2019.
In terms of deal activity, the US recorded 168 deals during Q3 2019, marking a drop of 15.6% over the previous quarter and a rise of 0.6% over the last four-quarter average.
The US medical devices industry venture financing deals in Q3 2019: Top deals
The top five medical devices industry venture financing deals accounted for 26.3% of the overall value during Q3 2019.
The combined value of the top five medical devices venture financing deals stood at $350m, against the overall value of $1.33bn recorded for the month.
The top five medical devices industry deals of Q3 2019 tracked by GlobalData were:
1) American Cancer Society, Andreessen Horowitz, Data Collective Venture Capital, Verily Life Sciences, GV Management Co, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, RA Capital Management, Roche Venture Fund, Section 32 and T. Rowe Price Associates’ $160m venture financing of Freenome
2) The $63m venture financing of Beta Bionics by ArrowMark Partners, Eventide Asset Management, Farallon Capital Management, Perceptive Advisors, RTW Investments and Soleus Capital Management
3) Dreamers Fund, KPCB Green Growth Fund, Lowercase Capital, Reproductive Health Investors Alliance, TriplePoint Capital, Union Square Ventures and Y Combinator Management’s $52m venture financing of Nurx
4) The $40m venture financing of Informed Data Systems by Bayer
5) Applied Ventures, Bold Capital Partners, Creative Ventures, Intel Capital, Longevity Vision Fund, Magnetar Capital, Nautilus Ventures, OSF HealthCare System, Rising Tide Fund Managers, Sony Innovation Fund and Wanxiang Healthcare Investments’ venture financing of eXo Imaging for $35m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.